HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
NEWS CRUNCH
Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam. The country received high-tech product for treatment of certain types of blood cancer. This was the first shipment under the 5-year contract with a local distributor. Previously, the Vietnamese patients could count only on the original products by Swiss global healthcare company F. Hoffmann-La Roche, but at a much higher price.

"Success of Russia's biosimilar rituximab has several ingredients. The product's high quality was proven in sizeable multinational clinical trials, yet its price is much lower than the originator's. This opened new opportunities to supply biosimilar rituximab to the patients who knew that the original product had been prohibitively expensive for them." Says BIOCAD's founder and CEO, Mr. Dmitri Morozov.

By now, BIOCAD has already signed more than a dozen agreements with the distribution and manufacturing companies in several countries of South-East Asia, such as the Philippines, Malaysia, Indonesia, and Thailand. Advanced Russian biotech products that are used for therapy of oncological and autoimmune diseases are in high demand WW. They are no inferior to the original products made by the leading Western companies, yet cost significantly less.

Source: BIOCAD
FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy